Cardlytics (NASDAQ:CDLX) Reaches New 1-Year High at $19.50

Cardlytics, Inc. (NASDAQ:CDLX) reached a new 52-week high during mid-day trading on Friday . The company traded as high as $19.50 and last traded at $19.25, with a volume of 65057 shares. The stock had previously closed at $19.17.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CDLX. JPMorgan Chase & Co. increased their price objective on shares of Cardlytics from $6.00 to $9.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Needham & Company LLC increased their price objective on shares of Cardlytics from $10.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, August 2nd.

Cardlytics Trading Up 1.0 %

The company has a market cap of $730.26 million, a price-to-earnings ratio of -1.68 and a beta of 1.83. The company has a quick ratio of 1.20, a current ratio of 1.20 and a debt-to-equity ratio of 0.96. The company’s 50-day moving average is $12.90 and its 200 day moving average is $8.04.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings results on Tuesday, August 1st. The company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.10. The company had revenue of $76.70 million for the quarter, compared to analyst estimates of $69.54 million. Cardlytics had a negative net margin of 128.92% and a negative return on equity of 25.96%.

Insider Buying and Selling at Cardlytics

In other news, insider Nicholas Hollmeyer Lynton sold 9,906 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $6.13, for a total value of $60,723.78. Following the transaction, the insider now directly owns 42,108 shares of the company’s stock, valued at $258,122.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Nicholas Hollmeyer Lynton sold 9,906 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $6.13, for a total value of $60,723.78. Following the transaction, the insider now directly owns 42,108 shares of the company’s stock, valued at $258,122.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Karim Saad Temsamani sold 25,574 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $6.13, for a total transaction of $156,768.62. Following the completion of the transaction, the chief executive officer now directly owns 24,426 shares in the company, valued at $149,731.38. The disclosure for this sale can be found here. Insiders have sold a total of 147,586 shares of company stock valued at $1,973,355 over the last ninety days. Corporate insiders own 0.78% of the company’s stock.

Hedge Funds Weigh In On Cardlytics

Several institutional investors and hedge funds have recently bought and sold shares of the company. American International Group Inc. boosted its holdings in Cardlytics by 5.5% in the 2nd quarter. American International Group Inc. now owns 16,262 shares of the company’s stock valued at $103,000 after purchasing an additional 849 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Cardlytics by 2.6% in the 1st quarter. Rhumbline Advisers now owns 34,150 shares of the company’s stock worth $1,878,000 after acquiring an additional 856 shares during the last quarter. FMR LLC lifted its holdings in shares of Cardlytics by 238.4% in the 2nd quarter. FMR LLC now owns 1,428 shares of the company’s stock worth $32,000 after acquiring an additional 1,006 shares during the last quarter. Check Capital Management Inc. CA lifted its holdings in shares of Cardlytics by 10.2% in the 2nd quarter. Check Capital Management Inc. CA now owns 11,900 shares of the company’s stock worth $75,000 after acquiring an additional 1,100 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Cardlytics by 7.2% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 17,580 shares of the company’s stock worth $392,000 after acquiring an additional 1,184 shares during the last quarter. 72.67% of the stock is currently owned by institutional investors and hedge funds.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.